Franz Vollenweider
Professor Emeritus of Psychiatry
Data updated
Research Footprint
Franz Vollenweider appears in 70 tracked papers (1997–2026), most studied alongside Psilocybin, LSD and MDMA, across Healthy Volunteers, Neuroimaging & Brain Measures and Schizophrenia.
Most-cited paper: Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action (1017 citations).
Frequent co-authors: Katrin Preller, Erich Seifritz and Matthias Kometer.
Publication Landscape
How the 70 papers Blossom tracks for Franz Vollenweider line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Franz Vollenweider's publishing grown?
SourcedTracked papers by publication year; 21 earlier papers published before 2012. Click a year for the running total.
Don't read as total output: only the 70 of 70 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Franz Vollenweider publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Franz Vollenweider publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Franz Vollenweider is a Swiss psychiatrist and a pioneer in the study of altered states of consciousness. He is a Professor Emeritus at the University of Zurich and the Director of the Heffter Research Center Zurich. His work has been fundamental in mapping the effects of psilocybin and LSD on the human brain using advanced neuroimaging, contributing significantly to our understanding of the serotonin system and the neurobiology of psychosis.
Key Impact
Key figure in brain imaging research and director of the Heffter Research Center Zurich.
Collaboration Network
50 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Franz Vollenweider's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Franz Vollenweider is associated with.
University of Zurich
academicWithin the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.
View stakeholder →Usona Institute
Non-ProfitUsona Institute is a US-based 501(c)(3) non-profit medical research organisation headquartered in Madison, Wisconsin. Usona develops and supports clinical research on psilocybin and other consciousness-expanding medicines with a mission-driven access model. Its psilocybin programme received FDA Breakthrough Therapy Designation for major depressive disorder in 2019. After completing the Phase 2 PSIL201 study, Usona launched the Phase 3 uAspire trial in 2024, a 240-participant randomised, double-blind multicentre study of 25 mg psilocybin with psychosocial support for adults with MDD. In April 2026, industry reporting said Usona confirmed it had received an FDA Commissioner National Priority Voucher for psilocybin in MDD, potentially shortening review if an NDA is filed and accepted. Usona is also exploring 5-MeO-DMT in early-stage research.
View stakeholder →